Showing results (4071-4080 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|July 24, 2025
Association of Social Vulnerability Index and Chimeric Antigen Receptor T-Cell Therapy Administration, 2018-2023Alireza Boloori, Emisa Nategh, Christopher T Su
The Oncologist|July 15, 2025
Cartoon: multicenter prospective observational study of Cardiovascular Toxicity of Trifluridine/Tipiracil in metastatic colorectal cancerFrancesco Leone, Valeria Fiamma, Francesca Crivelli, et al.
The Oncologist|July 14, 2025
Combination therapy for platinum-resistant ovarian cancer: a novel at-home regimen with envafolimab, lenvatinib, and etoposideBo Ding, Tianxiang Yu, Shiya Zheng, et al.
The Oncologist|July 15, 2025
Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinomaHelen H Moon, Melissa Kirker, Anup Abraham, et al.
The Oncologist|July 9, 2025
First-in-human phase I open-label study of the LAG-3 antagonist antibody INCAGN02385 in patients with select advanced or metastatic solid tumorsJohn D Powderly, Martin E Gutierrez, Ani S Balmanoukian, et al.
The Oncologist|July 9, 2025
Incidence and Risk of Hypertension and Proteinuria in Cancer Patients Treated with Lenvatinib: A Systematic Review and Meta-analysisYuma Shibutani, Atsuko Suzuki, Takuro Imaoka, et al.
The Oncologist|July 11, 2025
Effects of magnesium concentration on the regulation of nutrition and inflammation in nutritional support for cancer patientsXuelong Li, Wenjing Gong, Xiaoyan Yao, et al.
The Oncologist|June 28, 2025
Real-world testing of serum lactate dehydrogenase among patients with metastatic colorectal cancer in the United StatesHeinz-Josef Lenz, Orsolya Lunacsek, Helene Ostojic, et al.
The Oncologist|June 28, 2025
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumorsApostolia M Tsimberidou, Farshid Dayyani, David Sommerhalder, et al.
The Oncologist|June 26, 2025
Phase II study of avelumab and trastuzumab with FOLFOX chemotherapy in previously untreated HER2-amplified metastatic gastroesophageal adenocarcinomaMichael S Lee, Joseph Chao, Mary F Mulcahy, et al.
Pageof 571